{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:38Z","timestamp":1793896238109,"version":"4.8.0"},"reference-count":210,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.591577","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:56:11Z","timestamp":1603673771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":78,"title":["Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies"],"prefix":"10.3389","volume":"10","author":[{"given":"Laura","family":"Ondrisova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Mraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","journal-title":"Semin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.108","article-title":"Promises and pitfalls of targeted agents in chronic lymphocytic leukemia","volume":"3","author":"Lew","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.686.686","article-title":"The Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed\/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study","volume":"120","author":"Wilson","year":"2012","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109769","article-title":"Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase","volume":"111","author":"Aiba","year":"2008","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00079-0","article-title":"BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation","volume":"13","author":"Okada","year":"2000","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010590200","article-title":"The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase\/Akt signaling pathway and to the SHP2 tyrosine phosphatase","volume":"276","author":"Ingham","year":"2001","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","article-title":"miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1","volume":"124","author":"Mraz","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100873200","article-title":"Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk","volume":"276","author":"Saito","year":"2001","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park","year":"1996","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051591","article-title":"PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1","volume":"202","author":"Shinohara","year":"2005","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00836.x","article-title":"Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling","volume":"232","author":"Shinohara","year":"2009","journal-title":"Immunol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.20.5692","article-title":"PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization","volume":"20","author":"Kang","year":"2001","journal-title":"EMBO J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","article-title":"Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation","volume":"7","author":"Chan","year":"1997","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0211-0","article-title":"Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels","volume":"32","author":"Pavlasova","year":"2018","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-709519","article-title":"Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis","volume":"128","author":"Pavlasova","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0230-x","article-title":"MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells","volume":"33","author":"Cerna","year":"2019","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26376","article-title":"p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1","volume":"9","author":"Cerna","year":"2018","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559690","article-title":"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-855502","article-title":"miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels","volume":"132","author":"Musilova","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: how a complex biology gets more complex","volume":"29","author":"Musilova","year":"2015","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1861409","article-title":"miR-19 is a key oncogenic component of mir-17-92","volume":"23","author":"Olive","year":"2009","journal-title":"Genes Dev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.158","article-title":"Activation of the PI3K\/AKT pathway by microRNA-22 results in CLL B-cell proliferation","volume":"29","author":"Palacios","year":"2015","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473090","article-title":"The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop","volume":"122","author":"Psathas","year":"2013","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600944","article-title":"Batista FD. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1","volume":"25","author":"Carrasco","year":"2006","journal-title":"EMBO J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655.h8002655_2655_2663","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.11.3658.423k11_3658_3667","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245811","article-title":"The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment","volume":"116","author":"Steele","year":"2010","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200205)32:5&lt;1403::AID-IMMU1403<3.0.CO;2-Y","article-title":"Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22","volume":"32","author":"Ghia","year":"2002","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284984","article-title":"The Lymph Node Microenvironment Promotes B-cell Receptor Signaling, NF-kappaB Activation, and Tumor Proliferation in Chronic Lymphocytic Leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1204","article-title":"Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin\u2019s lymphoma","volume":"12","author":"Ruan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"B\u00fcrkle","year":"2007","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.129","article-title":"Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition","volume":"31","author":"Slinger","year":"2017","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13152","article-title":"Btk dosage determines sensitivity to B cell antigen receptor cross-linking","volume":"94","author":"Satterthwaite","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89904","article-title":"Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib","volume":"2","author":"Burger","year":"2017","journal-title":"JCI Insight"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567198","article-title":"Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK","volume":"124","author":"Krysov","year":"2014","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535799","article-title":"Roles for phosphoinositide 3-kinases, Bruton\u2019s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing","volume":"36","author":"Ortolano","year":"2006","journal-title":"Eur J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","article-title":"Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL","volume":"11","author":"Rendeiro","year":"2020","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.344","article-title":"miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton\u2019s tyrosine kinase inhibition with Ibrutinib","volume":"29","author":"Guinn","year":"2015","journal-title":"Leukemia"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.181","article-title":"Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia","volume":"31","author":"Saleh","year":"2017","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"New Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discovery"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.clml.2018.07.081","article-title":"LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors","volume":"18","author":"Brandhuber","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2032.2032","article-title":"First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects","volume":"128","author":"Neuman","year":"2016","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discovery"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.746842","article-title":"The Phospholipase C\u03b32 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J Biol Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-1742","article-title":"Abstract 1742: Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells","volume-title":"Experimental and Molecular Therapeutics","author":"Xue","year":"2015"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial","volume":"34","author":"Lenz","year":"2016","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.90196","article-title":"Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations","volume":"2","author":"Mondello","year":"2017","journal-title":"JCI Insight"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-020-0277-6","article-title":"SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas","volume":"10","author":"Munshi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-\u03baB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16463","article-title":"Genomic evolution of ibrutinib-resistant clones in Waldenstr\u00f6m macroglobulinaemia","volume":"189","author":"Jim\u00e9nez","year":"2020","journal-title":"Br J Haematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.190181","article-title":"MYD88 mutated and wild-type Waldenstr\u00f6m\u2019s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"key":"B98","unstructured":"BTK and PLCG2 Mutations In Patients With Chronic Lymphocytic Leukemia Relapsing On Ibrutinib: A European Research Initiative On CLL (ERIC) Study Based On Real-World Evidence\n            Scarf\u00f2L\n            BonfiglioS\n            SuttonL-A\n            Ljungstr\u00f6mV\n            PandzicT\n            CorteseD\n          25th Congress of the European Hematology Association2020"},{"key":"B99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"G\u00e1ng\u00f3","year":"2020","journal-title":"Int J Cancer"},{"key":"B100","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15613","article-title":"Unravelling the suboptimal response of TP53 -mutated chronic lymphocytic leukaemia to ibrutinib","volume":"184","author":"Guarini","year":"2019","journal-title":"Br J Haematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ccell.2015.02.005","article-title":"A functional landscape of resistance to ALK inhibition in lung cancer","volume":"27","author":"Wilson","year":"2015","journal-title":"Cancer Cell"},{"key":"B121","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110\u03b1 Inhibition Overcomes Stromal Cell\u2013Mediated Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B125","article-title":"Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies","volume-title":"Leukemia","author":"Lukas","year":"2020"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0205-2","article-title":"Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL","volume":"15","author":"Schmidl","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1349899","article-title":"Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen","volume":"59","author":"Schaffer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14588","article-title":"Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"key":"B135","unstructured":"Mechanisms Of Adaptation To Ibrutinib In High Risk Chronic Lymphocytic Leukemia\n            ForestieriG\n            Terzi di BergamoL\n            LohJW\n            SpinaV\n            ZucchettoA\n            CondoluciA\n          25th Congress of the European Hematology Association2020"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw131","article-title":"Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas","volume":"27","author":"Gaudio","year":"2016","journal-title":"Ann Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125396","article-title":"Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00411","article-title":"Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes","volume":"8","author":"Galicia-V\u00e1zquez","year":"2018","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","article-title":"Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin \u03b1-4-\u03b2-1 (VLA-4) with natalizumab can overcome this resistance","volume":"155","author":"Mraz","year":"2011","journal-title":"Br J Haematol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-015-0161-1","article-title":"Targeting Wnt pathway in mantle cell lymphoma-initiating cells","volume":"8","author":"Mathur","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","article-title":"CD40L mediated alternative NF\u03baB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma","volume":"9","author":"Rauert-Wunderlich","year":"2018","journal-title":"Cell Death Dis"},{"key":"B149","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-1298","article-title":"Abstract 1298: CD40L-CD40 signaling on B-cell lymphoma response to BTK inhibitors","volume-title":"Experimental and Molecular Therapeutics","author":"Sun","year":"2016"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80373-6","article-title":"In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death","volume":"90","author":"Lam","year":"1997","journal-title":"Cell"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1113276","article-title":"CD79B limits response of diffuse large B cell lymphoma to ibrutinib","volume":"57","author":"Kim","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.216218","article-title":"CXCR4 upregulation is an indicator of sensitivity to B-cell receptor\/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas","volume":"105","author":"Chen","year":"2020","journal-title":"Haematologica"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128899","article-title":"High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients","volume":"134","author":"Chiodin","year":"2019","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1286","article-title":"Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients","volume":"25","author":"Drennan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1675877","article-title":"The role of MYC in the transformation and aggressiveness of \u201cindolent\u201d B-cell malignancies","volume":"61","author":"Filip","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nature22353","article-title":"The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3\u03b2 inhibition","volume":"546","author":"Varano","year":"2017","journal-title":"Nature"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127255","article-title":"CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton\u2019s Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2010.07.003","article-title":"Prospective isolation of clonogenic mantle cell lymphoma-initiating cells","volume":"5","author":"Chen","year":"2010","journal-title":"Stem Cell Res"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.562570","article-title":"Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma","volume":"52","author":"Jung","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B165","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2141.2012.09123.x","article-title":"A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential","volume":"158","author":"Lee","year":"2012","journal-title":"Br J Haematol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091042","article-title":"Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells","volume":"9","author":"Medina","year":"2014","journal-title":"PloS One"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.233.233","article-title":"Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Leukemia","volume":"128","author":"O\u2019Brien","year":"2016","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700328","article-title":"Dual TORK\/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia","volume":"128","author":"Thijssen","year":"2016","journal-title":"Blood"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16386","article-title":"Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis","volume":"189","author":"Delvecchio","year":"2020","journal-title":"Br J Haematol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non\u2013germinal center B-cell\u2013like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015263","article-title":"A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL","volume":"2","author":"Ujjani","year":"2018","journal-title":"Blood Adv"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-019-0141-1","article-title":"Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide","volume":"8","author":"Albertsson-Lindblad","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08316.x","article-title":"The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies","volume":"151","author":"Buchner","year":"2010","journal-title":"Br J Haematol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"New Engl J Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718775","article-title":"B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma","volume":"129","author":"Dai","year":"2017","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574830","article-title":"PKC-\u03b2 as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL","volume":"124","author":"El-Gamal","year":"2014","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99436","article-title":"Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth","volume":"128","author":"Font\u00e1n","year":"2018","journal-title":"J Clin Invest"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2485","article-title":"MALT1 Inhibition Is Efficacious in Both Na\u00efve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia","volume":"77","author":"Saba","year":"2017","journal-title":"Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010272","article-title":"Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition","volume":"95","author":"Zhuang","year":"2010","journal-title":"Haematologica"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K Isoforms p110 and p110 Are Essential for Pre-B Cell Receptor Signaling and B Cell Development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signaling"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Invest Drugs"},{"key":"B201","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08151.x","article-title":"Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells","volume":"150","author":"de Frias","year":"2010","journal-title":"Br J Haematol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"DDDT"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142264","article-title":"Spotlight on copanlisib and its potential in the treatment of relapsed\/refractory follicular lymphoma: evidence to date","volume":"11","author":"Mensah","year":"2018","journal-title":"OTT"},{"key":"B206","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2770.2770","article-title":"Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment","volume":"128","author":"Ghia","year":"2016","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115304","article-title":"Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)","volume":"132","author":"Murali","year":"2018","journal-title":"Blood"},{"key":"B210","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1186\/s12885-019-6057-7","article-title":"Interleukin-6 mediates resistance to PI3K-pathway\u2013targeted therapy in lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.591577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:56:19Z","timestamp":1603673779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.591577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":210,"alternative-id":["10.3389\/fonc.2020.591577"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.591577","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"article-number":"591577"}}